| Callanan, David |
SIGLEC, NCT05839041: A Multiple Dose Study of AVD-104 for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) |
|
|
| Active, not recruiting | 2 | 300 | US | AVD-104, Avacincaptad | Aviceda Therapeutics, Inc. | Geographic Atrophy of the Macula, Macular Degeneration | 09/25 | 09/26 | | |
| Maturi, Raj K |
AO, NCT05904028: Home OCT-Guided Treatment Versus Treat and Extend for the Management of Neovascular AMD |
|
|
| Recruiting | 3 | 600 | Canada, US | Intravitreal injections of 6 mg faricimab on a Treat and Extend schedule, Intravitreal injections of 6 mg faricimab on a home optical coherence tomography-guided treatment schedule, Home OCT | Jaeb Center for Health Research, National Institutes of Health (NIH), National Eye Institute (NEI), Juvenile Diabetes Research Foundation | Neovascular Age-related Macular Degeneration | 07/27 | 07/27 | | |
| Recruiting | 3 | 560 | US | Fenofibrate, Placebo | Jaeb Center for Health Research, National Institutes of Health (NIH), National Eye Institute (NEI), Juvenile Diabetes Research Foundation, Roche Pharma AG, The Leona M. and Harry B. Helmsley Charitable Trust | Diabetic Retinopathy | 04/29 | 04/29 | | |
| Active, not recruiting | 2 | 128 | US | Tonabersat, Placebo | Jaeb Center for Health Research, National Institutes of Health (NIH), National Eye Institute (NEI), Juvenile Diabetes Research Foundation | Diabetic Macular Edema | 06/25 | 11/25 | | |
SIGLEC, NCT05839041: A Multiple Dose Study of AVD-104 for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) |
|
|
| Active, not recruiting | 2 | 300 | US | AVD-104, Avacincaptad | Aviceda Therapeutics, Inc. | Geographic Atrophy of the Macula, Macular Degeneration | 09/25 | 09/26 | | |
| Recruiting | 2 | 72 | US | 4D-150 IVT, Aflibercept IVT, Eylea | 4D Molecular Therapeutics | Diabetic Macular Edema, Diabetic Retinopathy | 02/28 | 07/28 | | |
| Recruiting | 1/2 | 215 | US | 4D-150 IVT, Aflibercept IVT | 4D Molecular Therapeutics | Neovascular (Wet) Age-Related Macular Degeneration | 11/25 | 11/26 | | |
| Recruiting | 1/2 | 63 | US | OCU410 | Ocugen | Geographic Atrophy | 09/25 | 09/25 | | |
| Recruiting | N/A | 400 | US | Immediate Vitrectomy, Deferred Vitrectomy | Jaeb Center for Health Research, National Institutes of Health (NIH), National Eye Institute (NEI), Juvenile Diabetes Research Foundation | Epiretinal Membrane | 12/26 | 12/26 | | |
| Solley, Wayne |
ARCHER II, NCT06510816: A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of ANX007 in Participants With Geographic Atrophy (GA) |
|
|
| Recruiting | 3 | 630 | US | ANX007, Sham Administration | Annexon, Inc. | Geographic Atrophy | 10/26 | 10/27 | | |
SIGLEC, NCT05839041: A Multiple Dose Study of AVD-104 for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) |
|
|
| Active, not recruiting | 2 | 300 | US | AVD-104, Avacincaptad | Aviceda Therapeutics, Inc. | Geographic Atrophy of the Macula, Macular Degeneration | 09/25 | 09/26 | | |
| MacCumber, Matthew |
SIGLEC, NCT05839041: A Multiple Dose Study of AVD-104 for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) |
|
|
| Active, not recruiting | 2 | 300 | US | AVD-104, Avacincaptad | Aviceda Therapeutics, Inc. | Geographic Atrophy of the Macula, Macular Degeneration | 09/25 | 09/26 | | |
| Patel, Nilam |
SIGLEC, NCT05839041: A Multiple Dose Study of AVD-104 for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) |
|
|
| Active, not recruiting | 2 | 300 | US | AVD-104, Avacincaptad | Aviceda Therapeutics, Inc. | Geographic Atrophy of the Macula, Macular Degeneration | 09/25 | 09/26 | | |
| Wilkes, Nichole |
OTX-TKI-2023-AMD-303, NCT06495918: Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration |
|
|
| Recruiting | 3 | 825 | US | OTX-TKI, Aflibercept | Ocular Therapeutix, Inc., Fortrea, Duke University | Neovascular Age-related Macular Degeneration | 01/27 | 01/27 | | |
